Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT03590652Phase 2Terminated
- Sponsor
- University of California, San Diego
- Start
- Oct 2018
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib in multiple myeloma (MM), sponsored by University of California, San Diego. Started Oct 2018; status: terminated.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03590652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03590652.